Deletion in theShigellaEnterotoxin Genes Further AttenuatesShigella flexneri2a Bearing Guanine Auxotrophy in a Phase 1 Trial of CVD 1204 and CVD 1208 | Zendy

Karen L. Kotloff | Zendy; Marcela F. Pasetti | Zendy; Eileen M. Barry | Zendy; James P. Nataro | Zendy; Steven S. Wasserman | Zendy; Marcelo B. Sztein | Zendy; William D. Picking | Zendy; Myron M. Levine | Zendy

Open Access

Deletion in theShigellaEnterotoxin Genes Further AttenuatesShigella flexneri2a Bearing Guanine Auxotrophy in a Phase 1 Trial of CVD 1204 and CVD 1208

Author(s) -

Karen L. Kotloff,

Marcela F. Pasetti,

Eileen M. Barry,

James P. Nataro,

Steven S. Wasserman,

Marcelo B. Sztein,

William D. Picking,

Myron M. Levine

Publication year - 2004

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/424680

Subject(s) - shigella flexneri , shigella , reactogenicity , microbiology and biotechnology , immunogenicity , virology , diarrhea , shigellosis , biology , shigella sonnei , medicine , immunology , antibody , gene , genetics , escherichia coli

We created a live, attenuated, oral Shigella vaccine by constructing a lineage of guanine auxotrophs and conducted a double-blind, placebo-controlled trial to ascertain (1) the attenuation profile of Delta guaBA Shigella flexneri 2a, which harbors deletions in the guanine nucleotide synthesis pathway (CVD 1204); (2) additional attenuation conferred by deletions in set and sen genes encoding Shigella enterotoxins (ShETs) 1 and 2, respectively (CVD 1208); and (3) the relative immunogenicity of these constructs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research